. In this Perspectives article, we propose that these therapeutic goals might be achieved by boosting natural immune regulatory mechanisms using compromised CNS, the mechanisms of their anti-injury and/or pro-repair actions and their use as cell-based therapies for CNS diseases or injuries. We conclude with a discussion of the technical barriers and challenges that remain to be solved before these approaches can be transformed into mainstream clinical regimens.
Regulatory lymphocytes

Regulatory T cells
Functions in CNS disorders. T reg cells are a naturally occurring, albeit rare, specialized T lymphocyte subpopulation characterized by the expression of cell surface markers CD4 and CD25 (also known as IL-2Rα) and the transcription factor forkhead box protein P3 (FOXP3) (Box 1). The major functions of T reg cells include suppression of the activities of other immune cells, maintenance of immune homeostasis and mediation of antigen-specific immune tolerance. As excessive neuroinflammation can amplify CNS pathologies, the immunosuppressive properties of T reg cells are expected to mitigate the effects of multiple diseases. Thus, the effects of T reg cells have been widely investigated as a therapeutic target in multiple sclerosis (MS), a common inflammatory demyelinating disease of the CNS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, genetic or pharmacological depletion of T reg cells exacerbates disease severity and is accompanied by local inflammation 11 . Conversely, intravenous infusions of isolated T reg cells, especially those derived from the CNS of EAE mice, alleviate demyelination and delay the progression of EAE 12 .
In addition to MS, the immunomodulatory effects of T reg cells confer protection in vivo in preclinical models of stroke 3, 4 , Parkinson disease 13 , Alzheimer disease (AD) 14 and amyotrophic lateral sclerosis (ALS) 15 . Although the bulk of evidence supports beneficial effects of T reg cells in CNS diseases, some studies nevertheless report detrimental effects. For example, immunosuppression of phagocytes by T reg cells can impair plaque clearance in a mouse model of AD 16 . Another study showed that depletion of T reg cells reduced stroke lesion volume and improved neurological functions 17 . These discrepancies might have arisen owing to the diverse and dynamic roles of T reg cells in cell-based approaches. Various types of immune cells, including regulatory T (T reg ) cells 3, 4 , regulatory B (B reg ) cells 5 , regulatory dendritic cells 6 , microglia, macrophages and monocytes 7 are known to alleviate inflammation and promote brain debris clearance. Intriguingly, these cells also execute unique regenerative functions during brain repair and regeneration, such as oligodendrocyte differentiation, myelin restoration, neural stem cell proliferation, neurovascular remodelling and rewiring of neural circuitry [8] [9] [10] ( Fig. 1) . Extensive preclinical testing and promising results from early clinical trials of immune cell therapy in autoimmune diseases and transplantation have kindled great interest in adoptive immune cell therapies, particularly for their ease of delivery, ability to naturally home in on target tissues and potential to change disease course. In this article, we present discoveries from the past few years on the functions of several beneficial immune cell populations in the Abstract | The healthy immune system has natural checkpoints that temper pernicious inflammation. Cells mediating these checkpoints include regulatory T cells, regulatory B cells, regulatory dendritic cells, microglia, macrophages and monocytes. Here, we highlight discoveries on the beneficial functions of regulatory immune cells and their mechanisms of action and evaluate their potential use as novel cell-based therapies for brain disorders. Regulatory immune cell therapies have the potential not only to mitigate the exacerbation of brain injury by inflammation but also to promote an active post-injury brain repair programme. By harnessing the reparative properties of these cells, we can reduce over-reliance on medications that mask clinical symptoms but fail to impede or reverse the progression of brain disorders. Although these discoveries encourage further testing and genetic engineering of regulatory immune cells for the clinical management of neurological disorders, a number of challenges must be surmounted to improve their safety and efficacy in humans. 
Mechanism of neuroprotection or regeneration.
Immunosuppression enabled by T reg cells involves multiple mechanisms (Fig. 1) . The involvement of many types of T effector cells has been indicated in the progression of neurological disorders. For example, CD4 + and CD8 + T cells promote tissue damage in mouse models of EAE 18 and stroke 19 . IL-17-producing γδ T cells also have a pivotal function in the evolution of ischaemic brain injury and accompanying neurological deficits 20, 21 . T reg cells inhibit the functions of these T effector cells via release of the immunosuppressive cytokines transforming growth factor-β (TGFβ), IL-10 and IL-35 (reFs 22, 23 ); induction of cytotoxicity towards T effector cells through the release of granzyme B and perforin 1 (reF.
24
); and expression of other immunoregulatory molecules such as galectin 1 (reF.
25
), lymphocyte activation gene 3 protein (LAG3) 26 , cytotoxic T lymphocyte antigen 4 (CTLA4) 27 , CD39 (also known as NTPDase 1) and CD73 (also known as 5′-NT) 28 . T reg cells also target a variety of other immune cells and convert antigen-presenting cells, such as dendritic cells, into cells that exhibit suppressive phenotypes 29 . T reg cells preserve the integrity of the blood-brain barrier after stroke via the interaction between programmed cell death 1 ligand 1 (PDL1) on T reg cells with programmed cell death protein 1 (PD1) on neutrophils, which inhibits production of matrix metalloproteinase 9 (MMP9) by neutrophils 4 . Membrane-bound TGFβ on the surface of T reg cells directly inhibits the effector functions of natural killer cells 30 . In genetic mouse models of AD, T reg cell amplification increases the numbers of plaque-associated microglia and restores cognitive functions, suggesting that T reg cells have a beneficial effect on microglial behaviour 14 . Another study in a model of intracerebral haemorrhage further confirmed that T reg cells shift responses of microglia and macrophages towards an anti-inflammatory phenotype through the IL-10-glycogen synthase kinase-3β (GSK3β)-phosphatase and tensin homologue (PTEN) axis in vitro and in vivo 31 . T reg cells possess additional functions beyond immunosuppression in CNS pathologies. For example, interactions between T reg cells and endothelial cells through signalling between CC-chemokine receptor 2 (CCR2) and its ligand CCchemokine ligand 2 (CCL2) could protect the blood-brain barrier and mitigate thrombolysis-induced brain haemorrhage 32 . Furthermore, T reg cell depletion impairs functional recovery and inhibits neural progenitor cell migration after stroke 33 , whereas adoptive transfer of T reg cells after stroke increases neural stem cell proliferation in an IL-10-dependent manner 8 . T reg cells can also promote the process of remyelination, independent of immunomodulation, by directly enhancing oligodendrocyte progenitor cell differentiation via production of CCN family member 3 (CCN3; also known as NovH) 9 . Taken together, these findings support a flexible and multifunctional nature of T reg cells. However, our understanding of the mechanisms underlying the neuroprotection afforded by T reg cells remains in its infancy, and the mechanisms discussed here await confirmation in further preclinical and clinical studies.
Preclinical approaches to boost the number and/or function of regulatory T cells. Brain injuries or diseases often result in peripheral immunosuppression and a reduction in the number of circulating T reg cells. The clinical literature on this topic is vast, and a few highlights are presented in TaBle 1 . For example, acute ischaemic stroke in humans immediately induces a dramatic loss of T reg cell numbers, followed by a sustained increase during the recovery phase 32 . However, the T reg cell response can vary depending on stroke volume, as the number of T reg cells increases after a smallsized stroke 34 . These clinical observations prompted the preclinical development of T reg cells as a cell therapy for CNS disorders and stimulated investigation of the mechanisms underlying the protective effects of these cells (TaBle 2) . To overcome the low frequency and intrinsic anergic properties of T reg cells, investigators developed approaches to boost the number and/or function of T reg cells, either via in vivo induction or exogenous administration of T reg cells after their in vitro expansion or activation. T reg cells have been successfully expanded ex vivo by crosslinking them with anti-CD3 and anti-CD28 antibodies in the presence of exogenous IL-2 (reF. 35 ). The addition of the serine-threonine protein kinase inhibitor rapamycin further prevents the acquisition of T effector cell functions and enables selective expansion of T reg cells 36 . However, the ex vivo expansion of sufficient numbers of T reg cells usually takes several weeks, rendering it difficult to quickly expand sufficient numbers of autologous (self) T reg cells from patients with abrupt brain injuries such as stroke or traumatic brain injury. Fortunately, the expansion of nonautologous (non-self) T reg cells derived from banked umbilical cord blood 37 or from human thymuses removed during paediatric cardiac surgery 38 provides another avenue for preparation of large numbers of T reg cells. Alternatively, T reg cells can be expanded in vivo using various stimulants, including low-dose IL-2 or complexes of IL-2 and the anti-IL-2 antibody JES6-1 (reF. 39 ), or monoclonal antibodies against death receptor 3 (DR3; also known as TNFRSF25) 40 . Another indirect in vivo T reg cell expansion strategy involves administration of FMS-related tyrosine kinase 3 ligand (FLT3L), a haematopoietic growth factor that stimulates the development of conventional myeloid dendritic cells and non-conventional plasmacytoid dendritic cells. Thus, FLT3L and rapamycin can synergistically induce antigen-specific expansion of T reg cells via selective expansion of plasmacytoid dendritic cells 41 . Protocols for the generation of antigenspecific T reg cells are being developed and could be effective in some CNS diseases without compromising general immune defences 42, 43 . The successful genetic engineering of chimeric antigen receptors (CARs) for the generation of alloantigenspecific T reg cells could further enhance their clinical translation in other diseases and in transplantation [44] [45] [46] . In summary, increasing numbers of preclinical studies support the therapeutic potential and restorative nature of exogenously or endogenously expanded T reg cells in CNS diseases. 
Regulatory B cells
Mechanism of neuroprotection.
Production of the immunosuppressive cytokine IL-10 is the major mechanism by which B reg cells down-modulate the function of other immune cells 48 . In addition, IL-35-producing B reg cells were identified in the past few years and were shown to regulate CNS autoimmune diseases 50 . 51, 52 .
Preclinical immune cell therapies that target regulatory B cells. Adoptive transfer of B10 cells effectively blunts disease progression and improves functional outcomes in models of MS and stroke 5, 52, 53 (TaBle 2 ). An additional promising B reg cell-related therapy entails the transient stimulation of bone marrow cells in vivo or in vitro through use of the Toll-like receptor 9 (TLR9) agonist CpG to generate B cell progenitors (CpG-proBs). When transferred into an EAE mouse model of MS at the onset of neurological symptoms, CpG-proBs can differentiate into IL-10-producing B reg cells and interrupt the course of EAE 53 . Although B reg cells are protective against many neurological diseases or injuries, other non-regulatory B cells could promote disease progression or impair brain recovery 47 . In addition, the functions of B10 cells might dominate only at specific time points. For example, in an EAE model of MS, B10 cells only slowed the initiation of the disease, whereas T reg cells inhibited disease progression at late phases of injury 48 . Thus, the success of therapeutic strategies targeting B reg cells will depend upon their specificity and the timing of treatment, as well as the type of immunosuppressive agents employed.
Microenvironmental cues
Owing to their broad disease relevance, factors that govern the differentiation and functional stability of regulatory immune cells have been a focal point of research in the past few years. As with other types of lymphocytes, the generation of regulatory lymphocytes relies on antigen-specific activation of T cell and B cell receptors and co-stimulation signals mediated by the B7-CD28 family of molecules. For example, myelin protein-specific T reg cells have been detected in the EAE mouse model for MS, where they have crucial roles in neuroprotection 54 . Similarly, B cell receptor recognition is important for B reg cell function and development in MS 55 . For most other CNS diseases, the antigens for T reg cell or B reg cell activation have not been identified. One possibility is that the intracellular contents released from injured CNS cells serve as antigens that activate regulatory immune cells. Interestingly, T reg cells might suppress T effector cells that have a variety of antigen specificities, and the suppression might be even more effective when the T reg cells and the suppressed T effector cells have the same antigen specificity 56 . Regulatory immune cells are regarded as intrinsically stable cell populations, and concerns regarding intrinsic T reg cell lineage plasticity and functional instability have been largely attributed to the misclassification of FOXP3 + non-T reg cells as T reg cells 57 . However, some external inputs, especially those in the highly inflammatory microenvironment within the compromised CNS, might perturb the stability of regulatory cells. For example, endothelial cells are thought to interact directly with T reg cells and improve their inhibitory properties 58, 59 . Human endothelial cells have also been reported to regulate the local inflammatory allogeneic response by promoting either a T helper 17 (T H 17) cell response or a T reg cell response depending on the cytokines in the microenvironment 60 . Increased interactions between T reg cells and the ischaemic brain endothelium could accelerate platelet accumulation and thereby increase the formation of microvascular thrombi 17 , which might underlie the detrimental effects of T reg cells in ischaemic stroke. In addition, TGFβ and IL-10 are known to increase the stability of T reg cells 61, 62 , whereas IL-6 can skew the differentiation of T reg cells towards a T H 17 cell fate 63 . Thus, cytokine accumulation in the neurovascular milieu of the pathological CNS probably influences the stability of infiltrated regulatory immune cells. Notably, cytokines released from gut microbiota and peripheral organs such as the spleen might also modulate the induction and stability of T reg cells or B reg cells 64, 65 . Such complexity in regulation of T reg cells and B reg cells could be a function of their crucial roles in immune regulation in pathological conditions.
Regulatory dendritic cells Functions of CNS dendritic cells
Dendritic cells are a heterogeneous population of professional, bonemarrow-derived antigen-presenting cells that link innate and adaptive immunity. They play an important part in the maintenance of self-tolerance in the healthy steady state 66 . Dendritic cells are known to travel from the CNS to cervical lymph nodes and dampen anti-CNS immune responses in the periphery 6 . Evidence also indicates that plasmacytoid dendritic cells in the CNS regulate the severity of relapsing EAE 67 . 
Dendritic cell-based therapies
Dendritic cell-based immunotherapy shows considerable promise for the restoration of tolerance in autoimmune disease 69, 70 . Dendritic cells can be modified ex vivo (for example, via autoantigen pulse) to induce a stable tolerogenic function. These cells can then be adoptively transferred to promote antigen-specific regulation of autoimmunity in vivo. Durable antigenspecific immune tolerance can also be induced in dendritic cells via sophisticated antigen delivery systems, such as synthetic, biodegradable nanoparticles or microparticles carrying encephalitogenic peptide antigens 71, 72 . Dendritic cells loaded with myelin basic protein (a brain autoantigen) and incubated with mitomycin C, which selectively downregulates intercellular adhesion molecule 1 and costimulatory molecule expression on these cells, confer resistance to subsequent EAE in mice 73 . Furthermore, transfer of embryonic stem cell-derived dendritic cells that express myelin-oligodendrocyte glycoprotein (MOG) with TNF-related apoptosisinducing ligand (TRAIL; also known as TNFSF10) or PDL1 can prevent EAE 74 . The effect of dendritic cell-based therapy on other CNS diseases or injuries has not yet been investigated.
Clinical trials Successes
Adoptive immune cell therapies were originally developed on the basis of the anticancer properties of immune cells, such as tumour-infiltrating lymphocytes 75 , and are currently most often employed for the clinical management of tumours, haematological malignancies, transplant rejection, autoimmune diseases and viral infections. In 2017, the FDA approved the first use of genetically engineered T cells with CARs for relapsing or refractory B cell precursor acute lymphoblastic leukaemia in patients under 25 years of age. This approval built on a long series of historical advances, some of which are highlighted in Fig. 2 . Most of these advances were in peripheral or systemic conditions rather than in brain disorders, although progress against CNS glioblastoma has also been made with CAR T cells 76 . One of the earliest uses of immune cells to treat brain disorders was the transplantation of autologous bone marrow-derived mononuclear cells. The early exploitation of these versatile cells helped researchers gain confidence in the feasibility, safety and efficacy of autologous cell infusions. Clinical trials have reported beneficial effects of autologous bone marrow-derived mononuclear cells when delivered by lumbar puncture after spinal cord injury or intracerebrally into the motor cortex in patients with ALS 77,78 (Fig. 2) .
Clinical trials of bone marrow-derived mononuclear cells have also been initiated in patients with stroke or cerebral palsy [79] [80] [81] . The main advantages of adoptive cell therapies include avoidance of the toxicity associated with drug regimens and the potential for reversal of the underlying disease process. In addition, adoptive cell therapies can be viewed as a 'living treatment' if the transferred cells continue to proliferate in the patient 82 . This proliferation is particularly important for neurological disorders, as most are progressive and have a long course and thus might benefit from sustained treatment. Importantly, the therapeutic time windows for immune cell therapies are expected to be far wider than those for classic neuroprotectants, which are generally given before, during or immediately after injury, whereas immune cells mainly target immunomodulation and CNS repair via long-term processes that are modifiable for weeks to months. Additionally, the therapeutic targets for immune cell treatments include not only CNS cells but also peripheral immune cells. Indeed, the immunomodulatory effects of regulatory immune cells might not be achieved via entry into the CNS. For example, T reg cells could provide CNS protection by ameliorating the deleterious activities of peripheral immune cells 4, 83 . This feature greatly improves the clinical feasibility of peripheral T reg cell manipulation as a non-invasive means of targeting the human CNS. Discoveries of the influence of the microbiota on T reg cell populations and the resulting effects on neurological conditions further support the indirect protective effects of peripheral T reg cells on the brain 65, 84 . For example, intestinal dysbiosis can lead to an increase in IL-10-producing T reg cells, which suppress trafficking of effector T cells from the gut to the leptomeninges and reduce brain injury after stroke 65 . Consequently, orally delivered agents might be developed in the future to modify or genetically engineer the gut microbiota to release factors that non-invasively and indirectly influence the CNS and impede the progression of brain disorders.
Many promising preclinical studies have been translated to clinical trials, which have shown that T reg cells can be isolated and expanded ex vivo, infused into patients and tolerated at high doses. The original clinical trials on ex vivo-expanded T reg cells revealed their immunosuppressive power to mitigate graft-versus-host disease (GVHD) and promote transplant tolerance 85, 86 (Fig. 2) .
Since these studies were conducted, a large body of work has demonstrated the promise of T reg cells in the treatment of leukaemia relapse, type 1 diabetes mellitus, chronic GVHD and lupus [86] [87] [88] . + plasmablasts release IL-10 and possess regulatory properties. With the fast pace of immunology research, increasing numbers of B reg cell subsets are being discovered. Furthermore, current research highlights the intrinsic plasticity of B cell subsets, enabling them to acquire specific profiles in a particular inflammatory microenvironment.
Extensive preclinical studies demonstrate the efficacy of adoptively transferred regulatory dendritic cells in the inhibition of GVHD, the promotion of long-term organ allograft survival and transplant tolerance and the suppression of autoimmune disorders 70 . In addition, local injections of immature, monocyte-derived dendritic cells induce antigen-specific tolerance of T cells to cognate antigens in healthy human volunteers 94 . These findings led to phase I clinical trials of autologous (either unpulsed or pulsed with autoantigen) regulatory dendritic cells in type 1 diabetes mellitus, rheumatoid arthritis and Crohn's disease 70 . These studies provided early evidence of the safety and biological activity of regulatory dendritic cell-based therapy 95 . Additionally, stable antigenspecific T cell hyporesponsiveness has been induced in vitro by regulatory dendritic cells generated from patients with MS for prospective clinical testing 96 .
Concerns and challenges
Despite early advances in adoptive cell therapies, serious concerns and challenges remain. To ensure future successes, the field must learn how to mitigate the potential inhibitory influences of adoptive cells on endogenous immune cells and on normal spleen function and the potential of adoptive cells to damage organs, such as by employing genetically engineered safety switches. In addition, the potential for adoptive cell transformation into malignancies should be monitored. Measures are also needed to alleviate the loss of tumour control functions by endogenous immune cells and the inability to control runaway infections, which can ensue after adoptive cell therapy. Furthermore, adoptive cell therapy can provoke cytokine release syndrome (including release of IL-6 and IFNγ), which results from activation of large numbers of leukocytes and can intensify into cytokine storms that demand pressor or ventilator support and sometimes culminate in death 97 . A creative method of managing these risks is to engineer safety switches by incorporating a conditional cellular suicide gene into the adoptive cells. One option is insertion of the gene encoding herpes simplex virus thymidine kinase, which thwarts DNA synthesis and kills cells but has the disadvantage of requiring several days to elicit its effect. A new approach involves the insertion of inducible caspase 9 into adoptive cells. Induced caspase 9 directly activates caspase 3 (the terminal effector of the mitochondrial apoptotic pathway) within hours and rapidly kills >99% of adoptive cells 98, 99 . Age and sex could also influence the effect of immune cell therapies. Sex differences in regulatory immune cells have been reported in experimental stroke, and increased levels of B reg cells and antiinflammatory CD11b (also known as ITGAM) + CD206 (also known as MMR) + microglia and macrophages have been observed in the ischaemic brain of female mice 100 . Ageing is also associated with increased numbers and heightened abilities of T reg cells to suppress effector T cells 101 .
However, the influence of these factors on the effectiveness of immune cell therapies has not been explored.
Some have argued that we do not sufficiently understand the complexity of interactions between T reg cells and T effector cells in the brain or the distinct effects of these cells in immune-competent versus immune-compromised individuals and that, consequently, we should avoid rushing prematurely into clinical trials on brain disorders 102 . An improved understanding of the kinetics of endogenous immune cell responses after human brain injury and their correlations with positive versus negative clinical outcomes might also increase the likelihood of success in future clinical trials. Other problems that remain to be addressed are the identification or optimization of the most appropriate source of immune cells, the best strategy for cell isolation and expansion, the best route of administration, the ideal timing of infusion, the optimum cell dose, maintenance of cell viability, successful cell homing to the target site and appropriate cell fate (for example, differentiation into the intended cell type). Limited information is available to address these issues. For example, the routes of immune cell administration vary across studies and are difficult to evaluate in parallel. For regulatory lymphocyte adoptive therapy, the less invasive intravenous route is commonly used. However, no systematic comparison of the effectiveness of different routes of administration has been conducted. TaBle 2 summarizes preclinical studies that employed regulatory lymphocyte adoptive transfer as interventions in models of neurological disorders. Although the doseresponse profile of T reg cell transfer has been explored in animal models 4, 32 , its application in humans needs further development.
Aside from the abovementioned issues, additional formidable barriers include standardization, quality control and identification of specific disease biomarkers and cell markers. For example, studies of B reg cells are hampered by lack of specific markers, and T reg cells can lose FOXP3 expression and convert to conventional T cells, thus complicating the identification of this population 103 .
Conclusions
For the future success of personalized cell therapies in brain disorders, therapeutic approaches must exhibit scalability and reasonable potency and efficacy. They must also have sustained effects without serious adverse events. Maus and colleagues described three facets of adoptive immunotherapeutics that must be optimized for clinical efficacy, which they defined as the soil (host immune system), the fertilizer (growth factors) and the seed (immune cell) 75 . Given the high heterogeneity of the human population, the complicating influences of biological variables such as age, sex, gut microbiota and comorbidities must also be considered carefully. Frequent monitoring of efficacy, safety and validated biomarkers will be necessary to refine and adjust the treatment according to the unique, dynamic immune status of each individual. We envision that immune cell-based therapies for the CNS will need to be personalized according to the individual's immune condition and re-adjusted during the natural progression of injury and recovery. Nevertheless, given the remarkable success of adoptive cell therapies in systemic conditions, we are cautiously optimistic about their potential to decelerate or perhaps even reverse the typically progressive nature of brain disorders.
